Cargando…
Targeting HER2 in breast cancer: overview of long-term experience
The ability to probe diseases at the genomic level has improved our understanding and enhanced the treatment of breast cancer. One important finding relates to the HER2 oncogene which encodes a novel transmembrane receptor that, when overexpressed, appears to confer growth and survival advantages to...
Autores principales: | Lantz, Evan, Cunningham, Ivan, Higa, Gerald M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971717/ https://www.ncbi.nlm.nih.gov/pubmed/21072285 |
Ejemplares similares
-
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021) -
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014) -
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
por: Strasser-Weippl, Kathrin, et al.
Publicado: (2015) -
An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022) -
An overview of prognostic factors for long-term survivors of breast cancer
por: Soerjomataram, Isabelle, et al.
Publicado: (2007)